Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA SNY has entered an agreement with Moderna Inc MRNA to manufacture its COVID-19 vaccine in the U.S.
The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks.
Sanofi will perform fill-and-finish at its Ridgefield facility in New Jersey to complete up to 200 million doses of the vaccine beginning in September. The financial details of the arrangement were not disclosed.
Since Sanofi’s contribution isn’t due to start until September, the Moderna vaccine doses it helps make might be directed toward vaccinating children under 18 years old, assuming the vaccine becomes authorized for them, or booster shots if they are needed to sustain immunity among adults, said Wall Street Journal.
In February, Sanofi had announced that it would support manufacturing for 12 million doses a month of Johnson & Johnson’s JNJ COVID-19 vaccine at its manufacturing site in France.
Before that, the company signed on to provide 125 million doses of the Pfizer Inc PFE - BioNTech SE BNTX vaccine for the EU in its Frankfurt plant.
Its attempt at a COVID-19 vaccine, Sanofi alongside GlaxoSmithKline Plc GSK, started a new Phase 2 study with a corrected shot’s formulation.
Last month, Sanofi and Translate Bio Inc TBIO started a human trial of their mRNA COVID-19 vaccine candidate.
Price Action: SNY shares are up 0.5% at $51.94, while MRNA shares are down 0.31% at $173.32 in the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga